Literature DB >> 18408659

In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation.

Tiziana Venesio1, Giovanna Chiorino, Antonella Balsamo, Alessandro Zaccagna, Consalvo Petti, Maria Scatolini, Alberto Pisacane, Ivana Sarotto, Franco Picciotto, Mauro Risio.   

Abstract

BRAF(V600E) mutation has been frequently reported in different types of melanocytic lesions, but its role in melanomagenesis is poorly understood, having been associated with either the proliferative-induced MAPK pathway activation or the acquisition of oncogene-driven senescence. The presence of BRAF alterations has been related to sun exposure, although the molecular mechanisms underlying this event are only partly known. To elucidate the relationships among BRAF/NRAS alterations, MAPK pathway activation, and sun exposure, we examined 22 acquired nevi and 18 cutaneus melanomas from 38 patients. Microdissected tissues from each lesion were subjected to BRAF/NRAS mutation analysis by sequencing, allele-specific PCR and pyrosequencing assay. The same lesions were also examined for the expression of phosphorylated ERK1/2. Phototype and an accurate history of sun exposure were evaluated for each patient. BRAF(V600E) mutation was detected in 50% of the acquired nevi and in 70% of the cutaneus melanomas in the absence of NRAS alterations. The fraction of alleles carrying BRAF(V600E) substitution was variable but strongly associated with sun exposure. In contrast, no relationship was evidenced between the presence of this mutation and patients' phototype, phosphorylated ERK1/2 expression, or Clark's level. Our findings indicate that in melanocytic lesions, BRAF(V600E) mutation can affect a subset of the cells and is associated with the type and quantity of sun exposure. This mutation is independent of the nevo-melanoma progression and unrelated to ERK phosphorylation, suggesting that alternative mechanisms to the MAPK activation are also involved in this type of transformation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18408659     DOI: 10.1038/modpathol.2008.41

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  16 in total

Review 1.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

2.  Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.

Authors:  Lisa Zimmer; Uwe Hillen; Elisabeth Livingstone; Mario E Lacouture; Klaus Busam; Richard D Carvajal; Friederike Egberts; Axel Hauschild; Mohammed Kashani-Sabet; Simone M Goldinger; Reinhard Dummer; Georgina V Long; Grant McArthur; André Scherag; Antje Sucker; Dirk Schadendorf
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

3.  Association between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma.

Authors:  Shaowei Wu; Helen Kuo; Wen-Qing Li; Alvaro Laga Canales; Jiali Han; Abrar A Qureshi
Journal:  Cancer Causes Control       Date:  2014-07-22       Impact factor: 2.506

Review 4.  Biological challenges of BRAF inhibitor therapy.

Authors:  Igor Puzanov; Patrick Burnett; Keith T Flaherty
Journal:  Mol Oncol       Date:  2011-02-16       Impact factor: 6.603

5.  Tanning and increased nevus development in very-light-skinned children without red hair.

Authors:  Jenny Aalborg; Joseph G Morelli; Stefan T Mokrohisky; Nancy L Asdigian; Tim E Byers; Robert P Dellavalle; Neil F Box; Lori A Crane
Journal:  Arch Dermatol       Date:  2009-09

6.  Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.

Authors:  Lucia Jilaveanu; Christopher Zito; Sandra J Lee; Katherine L Nathanson; Robert L Camp; David L Rimm; Keith T Flaherty; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

Review 7.  Genetics of melanocytic nevi.

Authors:  Mi Ryung Roh; Philip Eliades; Sameer Gupta; Hensin Tsao
Journal:  Pigment Cell Melanoma Res       Date:  2015-11       Impact factor: 4.693

Review 8.  Update on primary head and neck mucosal melanoma.

Authors:  Fernando López; Juan P Rodrigo; Antonio Cardesa; Asterios Triantafyllou; Kenneth O Devaney; William M Mendenhall; Missak Haigentz; Primož Strojan; Phillip K Pellitteri; Carol R Bradford; Ashok R Shaha; Jennifer L Hunt; Remco de Bree; Robert P Takes; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck       Date:  2015-05-22       Impact factor: 3.147

9.  Perianal melanoma with a BRAF gene mutation in a young Portuguese Roma native.

Authors:  Jennifer Tan
Journal:  BMJ Case Rep       Date:  2016-02-15

Review 10.  Biologically distinct subsets of nevi.

Authors:  Tova Rogers; Maria L Marino; Patricia Raciti; Manu Jain; Klaus J Busam; Michael A Marchetti; Ashfaq A Marghoob
Journal:  G Ital Dermatol Venereol       Date:  2016-04-27       Impact factor: 2.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.